UK markets close in 7 hours 38 minutes

Ultimovacs ASA (ULTI.OL)

Oslo - Oslo Delayed price. Currency in NOK
Add to watchlist
69.00-0.80 (-1.15%)
As of 09:34AM CEST. Market open.

Ultimovacs ASA

Ullernchausséen 64
Oslo 0379
47 41 38 00 80

Full-time employees23

Key executives

NameTitlePayExercisedYear born
Dr. Carlos de SousaChief Exec. OfficerN/AN/A1958
Mr. Hans Vassgård EidChief Financial OfficerN/AN/AN/A
Ms. Ingunn Hagen Westgaard Ph.D.Head of ResearchN/AN/AN/A
Mr. Audun TornesChief Technology OfficerN/AN/AN/A
Mr. Jens Egil Torbjorn Bjorheim M.D., Ph.D.Chief Medical OfficerN/AN/AN/A
Mr. Oivind Foss Ph.D.Head of Clinical OperationsN/AN/AN/A
Ms. Gudrun Troite Ph.D.Head of Project CoordinationN/AN/AN/A
Mr. Antonius BerkienChief Bus. OfficerN/AN/A1968
Prof. Gustav Gaudernack Ph.D.Chief Scientific OfficerN/AN/AN/A
Ms. Anne H. WorsoeHead of Investor Relations & CommunicationN/AN/AN/A
Amounts are as of , and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in NOK.


Ultimovacs ASA, a pharmaceutical company, develops immunotherapies for cancers. Its lead product candidate is UV1, a peptide-based vaccine that induces T cell response against the universal cancer antigen telomerase. The company was incorporated in 2011 and is headquartered in Oslo, Norway.

Corporate governance

Ultimovacs ASA’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.